Withdrawals due to adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
Probiotic showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: any adverse event · women with seizures due to catamenial epilepsy
Progesterone showed no clear difference in adverse events: any adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Mean adverse events: not reported · treating upper extremity deficits in individuals with hemiparesis after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · older people with age‐related memory loss
NSAIDs (celecoxib) may leads to higher adverse events – gastrointestinal compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with normal or abnormal lipid profiles
It is very uncertain whether all doses of cerivastatin changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by 6 weeks · people with agitation in dementia
It is very uncertain whether valproate preparations changes serious adverse events by 6 weeks compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Total adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
Withdrawals due to adverse events · adults with chronic neuropathic pain
1 finding from 1 review